WallStSmart

IRIDEX Corporation (IRIX)vsStryker Corporation (SYK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Stryker Corporation generates 47962% more annual revenue ($25.27B vs $52.58M). SYK leads profitability with a 13.2% profit margin vs -6.2%. IRIX appears more attractively valued with a PEG of 0.94. SYK earns a higher WallStSmart Score of 57/100 (C).

IRIX

Avoid

32

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 7.7Quality: 5.0
Piotroski: 4/9Altman Z: -2.51

SYK

Buy

57

out of 100

Grade: C

Growth: 6.0Profit: 6.5Value: 4.0Quality: 6.5
Piotroski: 3/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

IRIXUndervalued (+75.3%)

Margin of Safety

+75.3%

Fair Value

$5.79

Current Price

$0.86

$4.93 discount

UndervaluedFair: $5.79Overvalued
SYKSignificantly Overvalued (-57.3%)

Margin of Safety

-57.3%

Fair Value

$224.01

Current Price

$346.60

$122.59 premium

UndervaluedFair: $224.01Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IRIX1 strengths · Avg: 8.0/10
PEG RatioValuation
0.948/10

Growing faster than its price suggests

SYK1 strengths · Avg: 9.0/10
Market CapQuality
$118.55B9/10

Large-cap with strong market position

Areas to Watch

IRIX4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$15.51M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-126.4%2/10

ROE of -126.4% — below average capital efficiency

Revenue GrowthGrowth
-0.8%2/10

Revenue declined 0.8%

SYK3 concerns · Avg: 3.7/10
P/E RatioValuation
36.4x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
2.6%4/10

2.6% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : IRIX

The strongest argument for IRIX centers on PEG Ratio. PEG of 0.94 suggests the stock is reasonably priced for its growth.

Bull Case : SYK

The strongest argument for SYK centers on Market Cap.

Bear Case : IRIX

The primary concerns for IRIX are EPS Growth, Market Cap, Return on Equity.

Bear Case : SYK

The primary concerns for SYK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

IRIX profiles as a turnaround stock while SYK is a value play — different risk/reward profiles.

SYK carries more volatility with a beta of 0.78 — expect wider price swings.

SYK is growing revenue faster at 2.6% — sustainability is the question.

SYK generates stronger free cash flow (415M), providing more financial flexibility.

Bottom Line

SYK scores higher overall (57/100 vs 32/100). IRIX offers better value entry with a 75.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

IRIDEX Corporation

HEALTHCARE · MEDICAL DEVICES · USA

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic laser systems, delivery devices, and consumable instrumentation to treat vision-threatening eye diseases in ophthalmology. The company is headquartered in Mountain View, California.

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?